HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Checkpoint Therapeutics (NASDAQ:CKPT) and maintained a $34 price target.

March 22, 2024 | 6:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Checkpoint Therapeutics with a $34 price target.
The reiteration of a Buy rating and maintenance of a $34 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could lead to a positive short-term impact on CKPT's stock price. The high relevance and importance scores reflect the direct impact of analyst ratings on investor sentiment and stock performance, especially when the rating comes from a well-regarded source. The confidence score is high due to the clear and direct nature of the analyst's recommendation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100